Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Acute Toxicity: other routes

Currently viewing:

Administrative data

Endpoint:
acute toxicity: other routes
Type of information:
migrated information: read-across based on grouping of substances (category approach)
Adequacy of study:
other information
Study period:
08 Feb - 24 Feb 1994
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: basic data given

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1994
Report date:
1994

Materials and methods

Test guideline
Qualifier:
equivalent or similar to guideline
Guideline:
other: OECD No. 401, EEC Directive 92/69/EEC, Annex, Part B (B.1)
Deviations:
yes
Remarks:
i.v. ; This study was carried out with three dose levels (500, 750 and 1000 mg/kg bw, using five female albino rats for each dose level and five males for the two high dose levels (i.v.))
GLP compliance:
yes
Limit test:
no

Test material

Constituent 1
Reference substance name:
Vinasses, residue of fermentation
EC Number:
932-215-9
Molecular formula:
Not applicable (a generic molecular formula cannot be provided for this specific UVCB substance).
IUPAC Name:
Vinasses, residue of fermentation
Details on test material:
- Name of test material (as cited in study report): Prouvital, code GBR 50009
- Physical state / appearance: dark-brown, viscous liquid (described by sponsor as black liquid)
- Analytical purity: 100%
- Lot/batch No.: 93/204
- Storage condition of test material: in the dark at room temperature

Test animals

Species:
rat
Strain:
other: Wistar outbred rats Crl: WI (WU) BR
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Charles River Wiga, Sulzfeld, Germany
- Age at study initiation: 8 weeks old
- Housing: 5 animals/cage (stainless steel cages, 45x32x18 cm, fitted with wire screen floor and front)
- Diet (e.g. ad libitum): standard laboratory rat diet
- Water (e.g. ad libitum): tap water
- Acclimation period: 7 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 3
- Humidity (%): 42.5 - 72.5
- Air changes (per hr): ca. 10
- Photoperiod (hrs dark / hrs light): 12 /12

Administration / exposure

Route of administration:
intravenous
Vehicle:
other: demineralized water
Details on exposure:
The exact volume of the test dilution to be dosed was calculated for each animal individually and applied by syringe, equipped with a needle suitable for intravenous injection.
(viz. 2.5, 3.75 and 5 mL/kg body weight)
Doses:
500, 750 and 1000 mg/kg bw
(preliminary test: 2000, 1000, 750, 500, 250 mg/kg bw)
No. of animals per sex per dose:
5 (males without the low dose level group)
Control animals:
no
Details on study design:
- Duration of observation period following administration: 14 days (observations were made within 1 hour and within 4 hours after dosing, and subsequently at least once daily throughout an observation period of 14 days)
- Frequency of observations and weighing: immediately before dosing and on day 3, 7 and 14 of the study
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, gross pathological changes

Results and discussion

Effect levels
Sex:
male/female
Dose descriptor:
LD50
Effect level:
ca. 1 000 mg/kg bw
Based on:
test mat.
Remarks on result:
other: intravenous; some animals were reanimated
Mortality:
Two males and one female showed dyspnoea and coma, immediately after dosing (750 mg/kg bw) and needed reanimation to survive.
Immediately after dosing (1000 mg/kg bw) two males showed dyspnoea and coma and needed reanimation. Within ten minutes after dosing , despite reanimation, one male died. At the same doses of 1000 mg/kg bw four females showed dyspnoea and coma, immediately after dosing and needed reanimation to survive.
Clinical signs:
500 mg/kg bw: At 4 hours after dosing, sluggishness was observed in all females, while a swollen nose was observed at 1 and 4 hours after dosing.
750 mg/kg bw: Immediately after dosing until 4 hours after dosing, sluggishness was observed in all males and females. A swollen nose was observed in males at 1 hour after dosing and in females at 1-4 hours after dosing. In addition, the males showed swollen legs at 1-4 hours after dosing and females piloerection at 1 hour after dosing or at 4 hours after dosing. Two males and one female showed dyspnoea and coma.

1000 mg/kg bw: Two males showed dyspnoea and coma immediately after dosing. Immediately after dosing until 4 hours after dosing, sluggishness, swollen legs and nose were observed in all males (except one). In addition, the males showed a blue discolouration at 1 hour after dosing. One male showed vocalization at 4 hours after dosing. In females, sluggishness (at 1 hour after dosing), swollen nose (at 1-4 hours after dosing) and piloerection (at 4 hour after dosing) were observed. One female showed endogenous blue discolouration. Four females showed dyspnoea and coma immediately after dosing (and needed reanimation to survive).

all doses: During the remainder of 14-day observation period, no clinical symptoms were observed.
Body weight:
generally, all surviving animals gained weight during the 14-day observation period
one male and one female both treated with the 750 mg/kg bw dose level showed a very minor dip in body weight
Gross pathology:
Macroscopic examination of the animals did not reveal any treatment-related gross alterations at the end of the observation period. The one male that died also did not reveal treatment-related gross alterations.

Any other information on results incl. tables

Table 1: Summary of clinical symptoms and incidences

Observation

500 mg/kg bw

750 mg/kg bw

1000 mg/kg bw

Female

Male

Female

Male

Female

Sluggishness

5/5

5/5

5/5

5/5

5/5

Swollen nose

5/5

5/5

5/5

4/5

5/5

Swollen legs

 -

5/5

 -

4/5

 -

Piloerection

 -

 -

5/5

 

5/5

Blue discolouration

 -

 -

 -

4/5

1/5

Vocalization

 -

 -

 -

1/5

 -

Dyspnoea

 -

2/5

1/5

2/5

4/5

Coma

 -

2/5

1/5

2/5

4/5

Reanimation

 -

2/5

1/5

2/5

4/5

Death

 -

 -

 -

1/5

 -

Applicant's summary and conclusion